Thrombolysis with alteplase for acute ischemic stroke: Safe and effective outside the 3-hour time window?

Nature Clinical Practice Neurology

Volumn 5, Issue 2, 2009, Pages 70-71

  Leung, Thomas W H ^a   Wong, Ka Sing Lawrence ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FUNCTIONAL STATUS; HUMAN; MEDICAL AUDIT; MORTALITY; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 59849125509     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0993     Document Type: Note

References (7)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587
2. Wahlgren N et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 369: 275-282
3. Hacke W et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329
4. Kleindorfer D et al. (2008) National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 39: 924-928
5. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators (2004) Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768-774
6. Wahlgren N et al. (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 372: 1303-1309
7. Alberts MJ et al. (2005) Recommendations for comprehensive stroke centers: A consensus statement from the Brain Attack Coalition. Stroke 36: 1597-1616